Does Indomethacin Retard Disease Progression in Alzheimer's Disease?

H.P.H. Kremer, MD, PhD
University Medical Center Nijmegan (Nijmegan, The Netherlands)
Year Awarded:
2002
Grant Duration:
April 1, 2002 to March 31, 2003
Disease:
Alzheimer's Disease
Award Amount:
$139,000
Grant Reference ID:
A2001015
Award Type:
Standard
Award Region:
International

Does Indomethacin Retard Disease Progression in Alzheimer's Disease?

Details

Many studies have suggested that inflammatory mechanisms could play an important role in the deterioration of the brain in AD. Recent epidemiological studies in patients with arthritis found that the incidence of AD was lower than expected, possibly due to the long-term use of anti-inflammatory drugs. Small clinical studies have provided evidence to support this idea. Dr. Kremer is conducting tests to determine whether the anti-inflammatory drug indomethacin will slow the progression of mild or moderate AD. He is evaluating the effect of indomethacin on the decline of memory, behavior and functional status of patients with mild to moderate AD. Dr. Kremer will also evaluate the safety of long-term indomethacin treatment in patients with AD. If indomethacin is successful in treating early to moderate Alzheimer's disease, it would provide a cheap and effective medication for treating patients even in some of the poorest countries in the world.

Publications

de Jong D, Jansen RW, Verbeek MM, Kremer HP. [The possible suppression of Alzheimer's disease by nonsteroidal anti-inflammatory drugs]. Ned Tijdschr Geneeskd. 2002 Nov 2;146(44):2074-8. Review. Dutch.  

Don't miss out.
Receive research updates, inspiring stories, and expert advice
Please enter your first name.
Please enter your last name.
Keep me informed about: *
Please select at least one.
You must select at least one disease category.